Lineage Cell Therapeutics, Inc. Proceeds from Sale and Maturity of Held-to-maturity Securities
Lineage Cell Therapeutics, Inc. (LCTX) reported Proceeds from Sale and Maturity of Held-to-maturity Securities of $53.50 million for the 9-month period ending 2023-09-30, per its 10-Q filed 2023-11-09.
Discontinued › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities · last filed 2023-11-09
- Lineage Cell Therapeutics, Inc. proceeds from sale and maturity of held-to-maturity securities for the quarter ending 2023-09-30 was $5.83M.
- Lineage Cell Therapeutics, Inc. proceeds from sale and maturity of held-to-maturity securities for the quarter ending 2023-06-30 was $24.33M.
- Lineage Cell Therapeutics, Inc. proceeds from sale and maturity of held-to-maturity securities for the quarter ending 2023-03-31 was $23.33M.
- Lineage Cell Therapeutics, Inc. proceeds from sale and maturity of held-to-maturity securities for fiscal 2022 was $7.67M.
| Period end | Proceeds from Sale and Maturity of Held-to-maturity Securities 3 month | Proceeds from Sale and Maturity of Held-to-maturity Securities 6 month | Proceeds from Sale and Maturity of Held-to-maturity Securities 9 month | Proceeds from Sale and Maturity of Held-to-maturity Securities 12 month |
|---|---|---|---|---|
| 2023-09-30 | $5.83M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $30.16M derived: sum of 2 quarters · filed 2023-11-09 | $53.50M 10-Q · filed 2023-11-09 | |
| 2023-06-30 | $24.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $47.66M 10-Q · filed 2023-08-10 | ||
| 2023-03-31 | $23.33M 10-Q · filed 2023-05-11 | |||
| 2022-12-31 | $7.67M 10-K · filed 2023-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |